Figure 2.

Activation of myeloid and lymphoid cells after oral-SLGN treatment in healthy subjects. (A) Heatmap representation of the activation markers (CD38, CD69, CD40 and CD86) and pro-inflammatory cytokines (IL-6, IL-18, TNFα and IL-1β) on different subsets of immune cells. Change in the frequency of the activation markers and cytokines at 8 h compared to baseline among samples from the placebo (n = 5), 1.5 mg SLGN (n = 9) and 3.0 mg SLGN (n = 12) treatment groups were presented in the heatmap. Frequency of activation markers are represented for (B) CD40⁺, (C) CD86⁺ on mDCs and (D) CD40⁺ and (E) CD86⁺ on pDCs, respectively, from baseline and 8 h samples in placebo, 1.5 or 3.0 mg SLGN-treated individuals. Comparative analyses of frequencies of (F) CD69⁺ on MAIT, (G) CD16⁺CD56^bright and (H) CD16⁺CD56^dim on NK cell subsets are shown. Significance was calculated by a Wilcoxon matched-pairs signed-rank test, and p value ≤ 0.05 *, 0.01 ** and 0.001 *** show grades of significance. ns: no significance.